PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
6.44%
Revenue growth similar to 3088.T's 6.60%. Walter Schloss would see if both companies share industry tailwinds.
10.34%
Gross profit growth above 1.5x 3088.T's 2.76%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
32.32%
EBIT growth above 1.5x 3088.T's 8.34%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
35.65%
Positive operating income growth while 3088.T is negative. John Neff might view this as a competitive edge in operations.
36.95%
Net income growth above 1.5x 3088.T's 18.50%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
-31.52%
Negative EPS growth while 3088.T is at 18.50%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-31.52%
Negative diluted EPS growth while 3088.T is at 14.99%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
100.00%
Share change of 100.00% while 3088.T is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
100.00%
Diluted share change of 100.00% while 3088.T is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.06%
Negative 10Y revenue/share CAGR while 3088.T stands at 22.15%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-9.06%
Negative 5Y CAGR while 3088.T stands at 22.15%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-21.15%
Negative 3Y CAGR while 3088.T stands at 14.13%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-100.00%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-100.00%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
15.25%
Below 50% of 3088.T's 38.41%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
15.25%
Below 50% of 3088.T's 38.41%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
6.59%
Below 50% of 3088.T's 685.52%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.61%
Negative 3Y equity/share growth while 3088.T is at 37.04%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-100.00%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-99.47%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-2.66%
Inventory is declining while 3088.T stands at 3.19%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.83%
Asset growth above 1.5x 3088.T's 1.08%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-47.19%
We have a declining book value while 3088.T shows 2.09%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-76.30%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
52.94%
SG&A growth well above 3088.T's 26.34%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.